CD86 and neoplasm: Furthermore, tissue immunofluorescence staining evidenced a marked elevation in the expression of the M1 macrophage marker CD86 in tumor tissues treated with GEM + RP-6306@BxPC-3M (Fig. 8J), corroborating the robust antitumor efficacy of GEM + RP-6306@BxPC-3M in the CDX model with minimal systemic toxicity.